Literature DB >> 16778174

HSulf-1 inhibits angiogenesis and tumorigenesis in vivo.

Keishi Narita1, Julie Staub, Jeremy Chien, Kristy Meyer, Maret Bauer, Andreas Friedl, Sundaram Ramakrishnan, Viji Shridhar.   

Abstract

We previously identified HSulf-1 as a down-regulated gene in several tumor types including ovarian, breast, and hepatocellular carcinomas. Loss of HSulf-1, which selectively removes 6-O-sulfate from heparan sulfate, up-regulates heparin-binding growth factor signaling and confers resistance to chemotherapy-induced apoptosis. Here we report that HSulf-1 expression in MDA-MB-468 breast carcinoma clonal lines leads to reduced proliferation in vitro and reduced tumor burden in athymic nude mice in vivo. Additionally, xenografts derived from HSulf-1-expressing stable clones of carcinoma cells showed reduced vessel density, marked necrosis, and apoptosis, indicative of inhibition of angiogenesis. Consistent with this observation, HSulf-1-expressing clonal lines showed reduced staining with the endothelial marker CD31 in Matrigel plug assay, indicating that HSulf-1 expression inhibits angiogenesis. More importantly, HSulf-1 expression in the xenografts was associated with a reduced ability of vascular endothelial cell heparan sulfate to participate in a complex with fibroblast growth factor 2 (FGF-2) and its receptor tyrosine kinase FGF receptor 1c. In vitro, short hairpin RNA-mediated down-regulation of HSulf-1 in human umbilical vein endothelial cells (HUVEC) resulted in an increased proliferation mediated by heparan sulfate-dependent FGF-2, hepatocyte growth factor, and vascular endothelial growth factor 165 (VEGF165) but not by heparan sulfate-independent VEGF121. HSulf-1 down-regulation also enhanced downstream signaling through the extracellular signal-regulated kinase pathway compared with untreated cells. Consistent with the role of heparan sulfate glycosaminoglycan sulfation in VEGF-mediated signaling, treatment of HUVEC cells with chlorate, which inhibits heparan sulfate glycosaminoglycan sulfation and therefore mimics HSulf-1 overexpression, led to an attenuated VEGF-mediated signaling. Collectively, these observations provide the first evidence of a novel mechanism by which HSulf-1 modulates the function of heparan sulfate binding VEGF165 in proliferation and angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16778174     DOI: 10.1158/0008-5472.CAN-05-3582

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  65 in total

1.  Hypoxia negatively regulates heparan sulfatase 2 expression in renal cancer cell lines.

Authors:  Ashwani Khurana; Han W Tun; Laura Marlow; John A Copland; Keith Dredge; Viji Shridhar
Journal:  Mol Carcinog       Date:  2011-07-07       Impact factor: 4.784

2.  Evaluation of sulfatase-directed quinone methide traps for proteomics.

Authors:  Janina Lenger; Marius Schröder; Eva C Ennemann; Benjamin Müller; Chi-Huey Wong; Thomas Noll; Thomas Dierks; Sarah R Hanson; Norbert Sewald
Journal:  Bioorg Med Chem       Date:  2011-04-24       Impact factor: 3.641

3.  SULF1 inhibits proliferation and invasion of esophageal squamous cell carcinoma cells by decreasing heparin-binding growth factor signaling.

Authors:  Chun-Tao Liu; Sheng-Tao Zhu; Peng Li; Yong-Jun Wang; Hao Zhang; Shu-Tian Zhang
Journal:  Dig Dis Sci       Date:  2012-10-05       Impact factor: 3.199

Review 4.  Following up tumour angiogenesis: from the basic laboratory to the clinic.

Authors:  José L Orgaz; Beatriz Martínez-Poveda; Nuria I Fernández-García; Benilde Jiménez
Journal:  Clin Transl Oncol       Date:  2008-08       Impact factor: 3.405

Review 5.  Regulation of intracellular signaling by extracellular glycan remodeling.

Authors:  Randy B Parker; Jennifer J Kohler
Journal:  ACS Chem Biol       Date:  2010-01-15       Impact factor: 5.100

6.  HSulf-1 suppresses cell growth and down-regulates Hedgehog signaling in human gastric cancer cells.

Authors:  Hui-Yan Ma; Fang Zhang; Jie Li; Min-Li Mo; Zhao Chen; Lili Liu; Hai-Meng Zhou; Qing Sheng
Journal:  Oncol Lett       Date:  2011-09-02       Impact factor: 2.967

7.  Human Sulfatase 2 inhibits in vivo tumor growth of MDA-MB-231 human breast cancer xenografts.

Authors:  Sarah M Peterson; Andrea Iskenderian; Lynette Cook; Alla Romashko; Kristen Tobin; Michael Jones; Angela Norton; Alicia Gómez-Yafal; Michael W Heartlein; Michael F Concino; Lucy Liaw; Paolo G V Martini
Journal:  BMC Cancer       Date:  2010-08-13       Impact factor: 4.430

8.  Role of heparan sulfatases in ovarian and breast cancer.

Authors:  Ashwani Khurana; Daniah Beleford; Xiaoping He; Jeremy Chien; Viji Shridhar
Journal:  Am J Cancer Res       Date:  2013-01-18       Impact factor: 6.166

Review 9.  Heparin-degrading sulfatases in hepatocellular carcinoma: roles in pathogenesis and therapy targets.

Authors:  Jin-Ping Lai; James R Thompson; Dalbir S Sandhu; Lewis R Roberts
Journal:  Future Oncol       Date:  2008-12       Impact factor: 3.404

10.  Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors.

Authors:  Qinghai Liu; David H Nguyen; Qinghua Dong; Peter Shitaku; Kenneth Chung; On Ying Liu; Jonathan L Tso; Jason Y Liu; Veerauo Konkankit; Timothy F Cloughesy; Paul S Mischel; Timothy F Lane; Linda M Liau; Stanley F Nelson; Cho-Lea Tso
Journal:  J Neurooncol       Date:  2009-05-26       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.